Celgene (CELG) says based on a Phase III trial, the Committee for Medicinal Products for Human...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG) says based on a Phase III trial, the Committee for Medicinal Products for Human Use has recommended REVLIMID for approval regarding the treatment of transfusion-dependent anemia due to MDS when other therapies aren't sufficient or prove inadequate. Shares +.85% premarket after falling marginally Thursday following Q1 results.